D16H22S680E Inhibitors
Chemical inhibitors of D16H22S680E can impact its activity through various biochemical pathways. Methotrexate, a dihydrofolate reductase inhibitor, can deplete cellular levels of folate, a necessary cofactor for D16H22S680E, leading to the inhibition of its enzymatic functions that depend on folate. Similarly, Allopurinol operates as a xanthine oxidase inhibitor; if D16H22S680E is linked to purine metabolism, the presence of Allopurinol can decrease the production of uric acid and related metabolites, thereby inhibiting the activity of D16H22S680E. 5-Fluorouracil, which inhibits thymidylate synthase, can prevent the formation of thymidine monophosphate, causing a thymine deficiency that can impede the function of D16H22S680E if it is involved in DNA synthesis or repair.
Furthermore, Imatinib can inhibit the activity of D16H22S680E by targeting tyrosine kinase activity, essential for phosphorylation events within cellular signaling pathways. Rapamycin, known for its role as an mTOR inhibitor, can suppress the mTOR complex activity, which may be crucial for D16H22S680E function in related signaling pathways. Triclabendazole's ability to prevent tubulin polymerization can affect D16H22S680E if its activity is associated with cell division or cytoskeletal organization. Bortezomib, a proteasome inhibitor, can lead to an accumulation of proteins targeted for degradation, which can impact the function of D16H22S680E if it is part of protein degradation pathways. Celecoxib, a COX-2 inhibitor, can inhibit the production of prostaglandins, affecting D16H22S680E if it is involved in pathways influenced by COX-2 activity. Omeprazole, by inhibiting the hydrogen potassium ATPase, can alter the pH, which can inhibit D16H22S680E if its function is pH-dependent. Lastly, Zidovudine, a reverse transcriptase inhibitor, can inhibit D16H22S680E if it is involved in reverse transcription processes, and Gefitinib can block the EGFR tyrosine kinase activity, potentially inhibiting D16H22S680E if it is involved in EGFR-mediated signaling pathways.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Methotrexate is a dihydrofolate reductase inhibitor. D16H22S680E may require folate or folate derivatives for its activity. By inhibiting the reduction of dihydrofolate to tetrahydrofolate, Methotrexate would deplete the cellular levels of folate, thereby inhibiting the enzymatic function of D16H22S680E that relies on folate cofactors. | ||||||
Allopurinol | 315-30-0 | sc-207272 | 25 g | $128.00 | ||
Allopurinol acts as a xanthine oxidase inhibitor. If D16H22S680E is involved in purine metabolism, the inhibition of xanthine oxidase by Allopurinol could decrease the production of uric acid and related metabolites, potentially inhibiting D16H22S680E activity that is dependent on these metabolites. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
5-Fluorouracil is a thymidylate synthase inhibitor. If D16H22S680E is involved in DNA synthesis or repair, the action of 5-Fluorouracil would inhibit the production of thymidine monophosphate, leading to a thymine deficiency and subsequent inhibition of D16H22S680E activity related to thymidine triphosphate incorporation or DNA repair mechanisms. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor. If D16H22S680E has tyrosine kinase activity or is part of a signaling pathway involving tyrosine kinases, Imatinib would inhibit its activity by preventing phosphorylation events that D16H22S680E requires for its function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. In the event that D16H22S680E is involved in pathways regulated by the mTOR complex, Rapamycin would inhibit mTOR complex activity, which could suppress downstream signaling required for D16H22S680E function. | ||||||
Triclabendazole | 68786-66-3 | sc-213105 sc-213105A | 100 mg 1 g | $104.00 $120.00 | ||
Triclabendazole inhibits tubulin polymerization. If D16H22S680E plays a role in cell division or cytoskeletal organization, the inhibition of tubulin polymerization by Triclabendazole would disrupt microtubule formation and hence inhibit D16H22S680E activity associated with microtubule dynamics. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor. If D16H22S680E is involved in protein degradation pathways through the ubiquitin-proteasome system, Bortezomib would inhibit this process and could lead to the accumulation of proteins that are normally degraded, potentially inhibiting D16H22S680E activity through altered protein turnover. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $66.00 | 4 | |
Omeprazole is a proton pump inhibitor. If D16H22S680E function is pH-dependent or if it is involved in gastric acid secretion pathways, Omeprazole would inhibit the hydrogen potassium ATPase, altering the pH and potentially inhibiting D16H22S680E activity by preventing optimal proton concentration required for its function. | ||||||
3′-Azido-3′-deoxythymidine | 30516-87-1 | sc-203319 | 10 mg | $60.00 | 2 | |
Zidovudine is a reverse transcriptase inhibitor. If D16H22S680E is part of a pathway involving reverse transcription, such as in retroviral infection or reverse transcription of endogenous retroelements, Zidovudine would inhibit this process, and thereby inhibit D16H22S680E activity that is dependent on reverse transcriptase activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an epidermal growth factor receptor (EGFR) inhibitor. If D16H22S680E is involved in signaling pathways mediated by EGFR, Gefitinib would block EGFR tyrosine kinase activity | ||||||